Suppr超能文献

系统生物学方法鉴定潜在的癌症靶点受体及吲哚[2,1-a]异喹啉衍生物作为抗癌药物候选物的生物分子相互作用研究。

System Biology Approach to Identify Potential Receptor for Targeting Cancer and Biomolecular Interaction Studies of Indole[2,1-a]Isoquinoline Derivative as Anticancerous Drug Candidate Against it.

机构信息

Department of Biotechnology, G. B. Pant Engineering College, Pauri Garhwal, Uttarakhand, India.

Department of Applied Science and Humanities, G. B. Pant Engineering College, Pauri Garhwal, Uttarakhand, India.

出版信息

Interdiscip Sci. 2019 Mar;11(1):125-134. doi: 10.1007/s12539-017-0249-0. Epub 2017 Jul 26.

Abstract

Cancer is a public health concern which is spreading throughout the world. Different approaches have been employed to combat this disease. System biology approach has been used to understand the molecular mechanisms of drugs targeting cancer cell's receptor which have opened-up a window to develop effective drugs for it. We have demonstrated biomolecular interaction studies using the rational drug design of indole[2,1-a]isoquinoline derivative as a potent inhibitor against identified cancerous protein PIK3CA -a catalytic sub-unit of PI3K family protein-and compared its affinity with FDA approved drugs for receptors such as dactolisib, idelalisib, and several others such afatinib, avastin, ceritinib and crizotinib, etc.; by docking against potential receptor to set a cutoff value for our screening. Isoquinolines are small alkaloids with a vast variety of substitution depending upon their biogenetic pattern. Isoquinoline derivatives have been reported for their antimalarial, antibacterial, antifungal and anticancerous activities. The results obtained from the present studies conclude that membrane protein is an efficient drug that can be used to target cancer. Moreover, comparative study with ADMET prediction concludes that isoquinoline can be a potent drug for cancer treatment.

摘要

癌症是一个全球性的公共卫生问题。人们已经采用了不同的方法来对抗这种疾病。系统生物学方法被用于了解针对癌细胞受体的药物的分子机制,这为开发有效的药物提供了新的思路。我们已经使用吲哚[2,1-a]异喹啉衍生物的合理药物设计来证明生物分子相互作用研究,作为针对鉴定出的致癌蛋白 PIK3CA 的有效抑制剂 - PI3K 家族蛋白的催化亚基- 并比较其与 FDA 批准的用于受体的药物的亲和力,如 dactolisib、idelalisib 以及其他一些药物,如 afatinib、avastin、ceritinib 和 crizotinib 等;通过对接潜在的受体来为我们的筛选设定一个截止值。异喹啉是具有广泛取代的小分子生物碱,取决于其生物发生模式。异喹啉衍生物已被报道具有抗疟疾、抗菌、抗真菌和抗癌活性。本研究的结果表明,膜蛋白是一种有效的药物,可以用于靶向癌症。此外,与 ADMET 预测的比较研究表明,异喹啉可能是一种治疗癌症的有效药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验